Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Analyzing
the Generic Drugs Sector of the US Pharmaceutical Industry 2017”

report to their offering.

The United States is the biggest generic drugs market in the world. In
fact, nearly 80% of the prescriptions written in the US are for generic
drugs.

Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
2017 – a comprehensive coverage of the generic drugs market in the
United States. Beginning with a sectional description on generic drugs,
the report covers topics such as the impact of the generics sector on
major pharma companies, R&D strategies being implemented by major pharma
companies in the generics sector, the long debate over generic drugs
versus branded drugs, and much more – a cost analysis of branded drugs
versus generic drugs being a highlight.

An overview of the global generics sector builds up the scene for the
analysis of the US generics industry. The all-important Hatch-Waxman
Framework, the DEFRA Regulation, and other recent regulatory measures
are included in this analysis, along with the emerging issue of
promoting generic drug competition in the US Market.

Being a major section of the report, Promoting Generic Drug Competition
in the US Market covers topics such as issues with the FDA Approval
Process, the role of the Orange Book, the positive and negative outcomes
of the Hatch Waxman Act, the manipulation of this act, promoting methods
for generic drug availability, amongst other points of discussion.

Strategies for survival employed by branded manufacturers, the role of
generic drugs in lowering US drug re-importation, a case study on
generic antidepressants, the approval of the generic version of GSK’s
drug Coreg, the introduction of Bill S.438, and the substantial move by
Blue Cross in major changes to its drug plans, are discussed and
analyzed in this report.

We also include a Porter’s Five Forces analysis of the US Generic Drugs
Industry.

Analysis of major industry players such as Teva Pharmaceutical Industry,
Mylan N.V., Sandoz, Sanofi SA and others concludes this comprehensive
research report.

Key Topics Covered:

A. Executive Summary

B. What are Generic Drugs?

C. Overview of the Global Generics Sector

D. Generics Industry in the United States

E. Generics Industry in the US: Porter’s Five Forces Strategy Analysis

F. Pricing and Reimbursement of Generics in the US

G. Entry of Authorized Generics in the US Pharmaceutical Industry

H. Promoting Generic Drug Competition in the US Market

I. Strategies for Branded Manufacturers

J. Generic Drugs’ Role in US Drug Re-importation

K. Case Study: Generic Antidepressants

L. Case Study: Major Change to Drug Plan by Blue Cross

M. Leading Industry Players

– Allergan Plc

– Mylan N.V.

– Par Pharmaceutical Companies, Inc.

– Sandoz International GmbH

– Sanofi SA

– Teva Pharmaceutical Industries

For more information about this report visit http://www.researchandmarkets.com/research/8c46pw/analyzing_the

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Pharmaceuticals,
Generic
Drugs